582 related articles for article (PubMed ID: 17850661)
1. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.
Yau C; Fedele V; Roydasgupta R; Fridlyand J; Hubbard A; Gray JW; Chew K; Dairkee SH; Moore DH; Schittulli F; Tommasi S; Paradiso A; Albertson DG; Benz CC
Breast Cancer Res; 2007; 9(5):R59. PubMed ID: 17850661
[TBL] [Abstract][Full Text] [Related]
2. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
3. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes.
Smid M; Hoes M; Sieuwerts AM; Sleijfer S; Zhang Y; Wang Y; Foekens JA; Martens JW
Breast Cancer Res Treat; 2011 Jul; 128(1):23-30. PubMed ID: 20632083
[TBL] [Abstract][Full Text] [Related]
4. Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.
Fang M; Toher J; Morgan M; Davison J; Tannenbaum S; Claffey K
Cancer; 2011 May; 117(10):2024-34. PubMed ID: 21523713
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a transcriptional signature of breast cancer.
Feng Y; Li X; Sun B; Wang Y; Zhang L; Pan X; Chen X; Wang X; Wang J; Hao X
Breast Cancer Res Treat; 2010 Jul; 122(1):65-75. PubMed ID: 19728083
[TBL] [Abstract][Full Text] [Related]
6. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
[TBL] [Abstract][Full Text] [Related]
7. SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.
Chan HJ; Li H; Liu Z; Yuan YC; Mortimer J; Chen S
Oncotarget; 2015 Sep; 6(28):25815-27. PubMed ID: 26158350
[TBL] [Abstract][Full Text] [Related]
8. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
10. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
Anders CK; Hsu DS; Broadwater G; Acharya CR; Foekens JA; Zhang Y; Wang Y; Marcom PK; Marks JR; Febbo PG; Nevins JR; Potti A; Blackwell KL
J Clin Oncol; 2008 Jul; 26(20):3324-30. PubMed ID: 18612148
[TBL] [Abstract][Full Text] [Related]
11. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
[TBL] [Abstract][Full Text] [Related]
12. Challenges in projecting clustering results across gene expression-profiling datasets.
Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.
Andre F; Job B; Dessen P; Tordai A; Michiels S; Liedtke C; Richon C; Yan K; Wang B; Vassal G; Delaloge S; Hortobagyi GN; Symmans WF; Lazar V; Pusztai L
Clin Cancer Res; 2009 Jan; 15(2):441-51. PubMed ID: 19147748
[TBL] [Abstract][Full Text] [Related]
14. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
Liu D
Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
[TBL] [Abstract][Full Text] [Related]
15. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.
Kok M; Koornstra RH; Margarido TC; Fles R; Armstrong NJ; Linn SC; Van't Veer LJ; Weigelt B
J Pathol; 2009 Jul; 218(3):316-26. PubMed ID: 19353633
[TBL] [Abstract][Full Text] [Related]
16. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
[TBL] [Abstract][Full Text] [Related]
17. The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer.
Habashy HO; Rakha EA; Ellis IO; Powe DG
Breast Cancer Res Treat; 2013 Jul; 140(2):307-16. PubMed ID: 23887673
[TBL] [Abstract][Full Text] [Related]
18. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
19. Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers.
Graff-Baker AN; Orozco JIJ; Marzese DM; Salomon MP; Hoon DSB; Goldfarb M
Ann Surg Oncol; 2018 Oct; 25(10):3082-3087. PubMed ID: 29956094
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of HOTAIR expression is restricted to ER-negative breast cancers.
Gökmen-Polar Y; Vladislav IT; Neelamraju Y; Janga SC; Badve S
Sci Rep; 2015 Mar; 5():8765. PubMed ID: 25739705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]